The C-MIC-II Follow-Up Study
Launched by BERLIN HEALS GMBH · Jan 12, 2022
Trial Information
Current as of November 14, 2025
Recruiting
Keywords
ClinConnect Summary
The C-MIC-II Follow-Up Study is looking at the effects of a special medical device called the C-MIC System, which is designed to help treat heart failure by sending a small electrical current to the heart. This study is specifically for patients who have already received this device in a previous trial and aims to gather more information about how well it works over time.
To join the study, participants need to be between the ages of 65 and 74 and must have given written consent to take part. It's important to note that those who are not able or willing to attend the study visits will not be eligible. If you take part, you can expect to attend regular visits where the researchers will monitor your health and gather feedback about your experience with the device. This study is currently recruiting participants of all genders, and it provides a chance to contribute to our understanding of treatments for heart failure.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients who have received a C-MIC System during the C-MIC-II Study.
- • Informed consent in writing from the patient.
- Exclusion Criteria:
- • Patients who are unwilling or unable to participate in the study visits.
- • Vulnerable Patients.
About Berlin Heals Gmbh
Berlin Heals GmbH is a forward-thinking clinical trial sponsor based in Berlin, Germany, dedicated to advancing medical research and innovation. With a focus on developing innovative therapies across various therapeutic areas, the company collaborates with leading research institutions and healthcare professionals to facilitate robust clinical trials. Berlin Heals GmbH is committed to upholding the highest ethical standards and regulatory compliance, ensuring the safety and well-being of participants while striving to bring groundbreaking treatments to market. Through its expertise in trial design and execution, the company aims to contribute significantly to the improvement of patient outcomes and the advancement of healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Belgrade, Serbia
Belgrade, Serbia
Zagreb, Croatia
Sarajevo, Bosnia And Herzegovina
Banja Luka, Bosnia And Herzegovina
Skopje, North Macedonia
Patients applied
Trial Officials
Peter Goettel, MD
Study Chair
Berlin Heals GmbH
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials